Fulgent Genetics, Inc. — fact timeline

Fulgent Genetics, Inc. reported first quarter ended March 31, 2026 results: revenue 71.1 million, net income -24.8 million, EPS -0.80. Guidance reaffirmed.

“for fiscal year 2026 • Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash • Revenue of $71.1 million • GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross profit of $23.0 million, or Non-GAAP gross margin of 32.3% • GAAP loss of $24.8 million, or”

Fulgent Genetics, Inc. completed an acquisition involving Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting (closed 2026-03-17).

“On March 17, 2026, the transactions contemplated by the APA were completed (the "APA Closing").”

Fulgent Genetics, Inc. completed an acquisition involving Inform Diagnostics, Inc. (closed 2026-03-17).

“On March 17, 2026, the transactions contemplated by the PSA were completed (the "PSA Closing").”

Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2024-05-16 meeting.

“Proposal 3 Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstained Broker Non-Vote 19,786,239 573,411 25,950 4,095,268”

Fulgent Genetics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-16 meeting.

“Proposal 2 Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes For Votes Against Votes Abstained Broker Non-Vote 24,238,701 222,804 19,363 —”

Fulgent Genetics, Inc. shareholders approved Election of directors at the 2024-05-16 meeting.

“Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Votes For Votes Withheld Broker Non-Vote Ming Hsieh 20,071,185 314,415 4,095,268 Michael Nohaile, Ph.D. 17,462,830 2,922,770 4,095,268 Regina Groves 17,487,701 2,897,899 4,095,268 Linda Marsh 15,854,682 4,530,918 4,095,268”

Fulgent Genetics, Inc. reported first quarter ended March 31, 2024 results: revenue $64.5 million, net income loss of $13.5 million, EPS $0.45 per share. Guidance reaffirmed.

“Fulgent Reports First Quarter 2024 Financial Results • Total Revenue of $64.5 million • Core Revenue grows 1% year-over-year to $63.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million”